2 assets in Fibromyxoid Tumor

Therapeutic assets addressing Fibromyxoid Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Fibromyxoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Fibromyxoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)